Is liquid biopsy the future commutator of decision-making in liver transplantation for hepatocellular carcinoma?

Liver transplant (LT) is the most favorable treatment option for patients with early stage hepatocellular carcinoma (HCC). Numerous attempts have been pursued to establish eligibility criteria and select HCC patients for LT, leading to various systems that essentially integrate clinico-morphological variables. Lacking of sufficient granularity to recapitulate the biological complexity of the disease, all these alternatives display substantial limitations and are thus undeniably imperfect. Liquid biopsy, defined as the molecular analysis of circulating analytes released by a cancer into the bloodstream, was revealed as an incomparable tool in the management of cancers, including HCC. It appears as an ideal candidate to refine selection criteria of LT in HCC. The present comprehensive review analyzed the available literature on this topic. Data in the field, however, remain scarce with only 17 studies. Although rare, these studies provided important and encouraging findings highlighting notable prognostic values and supporting the contribution of liquid biopsy in this specific clinical scenario. These results underpinned the critical and urgent need to intensify and accelerate research on liquid biopsy, in order to determine whether and how liquid biopsy may be integrated in the decision-making of LT in HCC.

[1]  N. Demartines,et al.  Basic Science with Preclinical Models to Investigate and Develop Liquid Biopsy: What Are the Available Data and Is It a Fruitful Approach? , 2022, International journal of molecular sciences.

[2]  S. Gallinger,et al.  Recipient and Donor Outcomes After Living-Donor Liver Transplant for Unresectable Colorectal Liver Metastases , 2022, JAMA Surgery.

[3]  G. Sapisochin,et al.  Liver Transplantation for Intrahepatic Cholangiocarcinoma: Ready for Prime Time? , 2021, Hepatology.

[4]  C. Combescure,et al.  Predicting recurrence of hepatocellular carcinoma after liver transplantation using a novel model that incorporates tumor and donor‐related factors , 2021, Transplant international : official journal of the European Society for Organ Transplantation.

[5]  Jae Geun Lee,et al.  Circulating Cancer Stem Cells Expressing EpCAM/CD90 in Hepatocellular Carcinoma: A Pilot Study for Predicting Tumor Recurrence after Living Donor Liver Transplantation , 2021, Gut and liver.

[6]  Jia Fan,et al.  Plasma MicroRNA Panel Predicts Early Tumor Recurrence in Patients with Hepatocellular Carcinoma after Liver Transplantation , 2021, Journal of Cancer.

[7]  H. Tseng,et al.  Circulating Tumor Cell–Based Messenger RNA Scoring System for Prognostication of Hepatocellular Carcinoma: Translating Tissue‐Based Messenger RNA Profiling Into a Noninvasive Setting , 2021, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[8]  A. Goldenberg,et al.  The Toronto Postliver Transplantation Hepatocellular Carcinoma Recurrence Calculator: A Machine Learning Approach , 2021, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[9]  Wei Liu,et al.  Association of phenotypic transformation of circulating tumor cells and early recurrence in patients with hepatocellular carcinoma following liver transplantation. , 2021, Asian journal of surgery.

[10]  R. Sebra,et al.  Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer , 2021, Gut.

[11]  R. Dhanasekaran,et al.  Down-staging Outcomes for Hepatocellular Carcinoma: Results from the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium. , 2021, Gastroenterology.

[12]  M. L. de la Mata,et al.  Clearance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection or Liver Transplantation , 2021, Cancers.

[13]  N. Demartines,et al.  Experimental Models of Liquid Biopsy in Hepatocellular Carcinoma Reveal Clone‐Dependent Release of Circulating Tumor DNA , 2021, Hepatology communications.

[14]  T. Luedde,et al.  Serum levels of circulating microRNA-107 are elevated in patients with early-stage HCC , 2021, PloS one.

[15]  N. Demartines,et al.  The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication , 2021, Cancers.

[16]  Ya Cao,et al.  Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[17]  J. Llovet,et al.  Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma , 2020, Oncogene.

[18]  T. Luedde,et al.  Circulating levels of microRNA193a-5p predict outcome in early stage hepatocellular carcinoma , 2020, PloS one.

[19]  Amber L. Simpson,et al.  Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers , 2020, Cell.

[20]  Qiang Zhao,et al.  Analysis of preoperative circulating tumor cells for recurrence in patients with hepatocellular carcinoma after liver transplantation , 2020, Annals of translational medicine.

[21]  H. Tseng,et al.  Hepatocellular Carcinoma–Circulating Tumor Cells Expressing PD‐L1 Are Prognostic and Potentially Associated With Response to Checkpoint Inhibitors , 2020, Hepatology communications.

[22]  C. Strassburg,et al.  Synergistic effects of extracellular vesicle phenotyping and AFP in hepatobiliary cancer differentiation , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[23]  L. Mariani,et al.  Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. , 2020, The Lancet. Oncology.

[24]  Yanwei Luo,et al.  High expression of circulating exosomal circAKT3 is associated with higher recurrence in HCC patients undergoing surgical treatment. , 2020, Surgical oncology.

[25]  M. Schmelzle,et al.  Increased Cell-Free DNA Plasma Concentration Following Liver Transplantation Is Linked to Portal Hepatitis and Inferior Survival , 2020, Journal of clinical medicine.

[26]  Namita Srivastava,et al.  The Machine‐Learning Approach , 2020, Machine Learning for iOS Developers.

[27]  A. Villanueva,et al.  Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma , 2020, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[28]  Chi-Chih Wang,et al.  Circulating exosomal miR‐92b: Its role for cancer immunoediting and clinical value for prediction of posttransplant hepatocellular carcinoma recurrence , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[29]  W. Tak,et al.  Circulating exosomal noncoding RNAs as prognostic biomarkers in human hepatocellular carcinoma , 2018, International journal of cancer.

[30]  Jing Xu,et al.  Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines , 2018, Journal of Extracellular Vesicles.

[31]  Boris M. Hartmann,et al.  High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma , 2018, Scientific Reports.

[32]  B. Naini,et al.  A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma , 2018, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[33]  Yugang Wang,et al.  Decreased levels of serum exosomal miR‐638 predict poor prognosis in hepatocellular carcinoma , 2018, Journal of cellular biochemistry.

[34]  Jie Zhou,et al.  Analysis of circulating tumor cells in patients with hepatocellular carcinoma recurrence following liver transplantation , 2018, Journal of Investigative Medicine.

[35]  M. Mahajan,et al.  A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma , 2018, Oncogene.

[36]  Zhiyu Qian,et al.  Application of a novel liquid biopsy in patients with hepatocellular carcinoma undergoing liver transplantation , 2018, Oncology letters.

[37]  W. Guo,et al.  Circulating Tumor Cells from Different Vascular Sites Exhibit Spatial Heterogeneity in Epithelial and Mesenchymal Composition and Distinct Clinical Significance in Hepatocellular Carcinoma , 2017, Clinical Cancer Research.

[38]  F. Lammert,et al.  Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma. , 2017, Journal of hepatology.

[39]  Neil Mehta,et al.  Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant , 2017, JAMA oncology.

[40]  P. Parrilla,et al.  Oncological Evaluation by Positron-emission Tomography, Circulating Tumor Cells and Alpha Fetoprotein in Patients With Hepatocellular Carcinoma on the Waiting List for Liver Transplantation. , 2016, Transplantation proceedings.

[41]  David Jamieson,et al.  Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma? , 2016, Journal of hepatology.

[42]  J. Joh,et al.  Serum Tumor Markers Provide Refined Prognostication in Selecting Liver Transplantation Candidate for Hepatocellular Carcinoma Patients Beyond the Milan Criteria , 2016, Annals of surgery.

[43]  Chang Xian Li,et al.  Early-phase circulating miRNAs predict tumor recurrence and survival of hepatocellular carcinoma patients after liver transplantation , 2016, Oncotarget.

[44]  A. Minguela,et al.  Comparison of Two Types of Liquid Biopsies in Patients With Hepatocellular Carcinoma Awaiting Orthotopic Liver Transplantation. , 2015, Transplantation Proceedings.

[45]  Gary K. Schwartz,et al.  Tumour exosome integrins determine organotropic metastasis , 2015, Nature.

[46]  J. Dufour,et al.  Total tumor volume and alpha‐fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation , 2015, Hepatology.

[47]  Xiao-jing Yang,et al.  A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. , 2015, The Lancet. Oncology.

[48]  T. Tsunoda,et al.  Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy , 2015, Cellular and molecular gastroenterology and hepatology.

[49]  Michael A. Hollingsworth,et al.  Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver , 2015, Nature Cell Biology.

[50]  A. Villanueva,et al.  Liquid biopsy in liver cancer. , 2015, Discovery medicine.

[51]  Jessica Zucman-Rossi,et al.  Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets , 2015, Nature Genetics.

[52]  Y. N. Park,et al.  Increased Expression of Circulating Cancer Stem Cell Markers During the Perioperative Period Predicts Early Recurrence After Curative Resection of Hepatocellular Carcinoma , 2015, Annals of Surgical Oncology.

[53]  K. Mimori,et al.  Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation , 2015, British Journal of Cancer.

[54]  Hiromi Nakamura,et al.  Trans-ancestry mutational landscape of hepatocellular carcinoma genomes , 2014, Nature Genetics.

[55]  S. Fan,et al.  Prediction of Posthepatectomy Recurrence of Hepatocellular Carcinoma by Circulating Cancer Stem Cells: A Prospective Study , 2011, Annals of surgery.

[56]  Ruifa Han,et al.  Clinical values of AFP, GPC3 mRNA in peripheral blood for prediction of hepatocellular carcinoma recurrence following OLT , 2011, Hepatitis monthly.

[57]  J. Trotter,et al.  Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[58]  S. Cheung,et al.  Albumin mRNA in Plasma Predicts Post-Transplant Recurrence of Patients With Hepatocellular Carcinoma , 2008, Transplantation.

[59]  Y. Takeda,et al.  Detection of AFP mRNA‐expressing cells in the peripheral blood for prediction of HCC recurrence after living donor liver transplantation , 2007, Transplant international : official journal of the European Society for Organ Transplantation.

[60]  K. Hatakeyama,et al.  Comparison between human-telomerase reverse transcriptase mRNA and alpha-fetoprotein mRNA as a predictive value for recurrence of hepatocellular carcinoma in living donor liver transplantation. , 2006, Transplantation proceedings.

[61]  M. Plebani,et al.  Clinical significance of alpha-fetoprotein mRNA in blood of patients with hepatocellular carcinoma. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[62]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[63]  Bernard Lacour,et al.  Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer , 2004, Hepatology.

[64]  L. Ferrell,et al.  Liver transplantation for hepatocellular carcinoma: Comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[65]  V. Mazzaferro,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.

[66]  J. Guerrero,et al.  Detection of p53 Mutations in Circulating DNA of Transplanted Hepatocellular Carcinoma Patients as a Biomarker of Tumor Recurrence. , 2016, Advances in experimental medicine and biology.

[67]  L. Mariani,et al.  Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. , 2009, The Lancet. Oncology.

[68]  J. Manson,et al.  Prospective Study of , 2007 .

[69]  A. Tannapfel,et al.  Prospective evaluation of circulating hepatocytes by alpha-fetoprotein messenger RNA in patients with hepatocellular carcinoma. , 2002, Surgery.

[70]  D. Woodfield Hepatocellular carcinoma. , 1986, The New Zealand medical journal.